SCHEIBLER LUKAS 4
4 · Apellis Pharmaceuticals, Inc. · Filed Feb 22, 2023
Insider Transaction Report
Form 4
SCHEIBLER LUKAS
See Remarks
Transactions
- Award
Stock Option (Right to Buy)
2023-02-21+14,023→ 14,023 totalExercise: $35.46Exp: 2032-01-20→ Common Stock (14,023 underlying) - Award
Common Stock
2023-02-21+9,886→ 70,358 total - Tax Payment
Common Stock
2023-02-21$58.50/sh−715$41,828→ 69,643 total
Footnotes (3)
- [F1]The Reporting Person was granted performance-based restricted stock units ("PRSUs") on January 21, 2022, the vesting of which was subject to the attainment of each of the following events: (i) the submission of a new drug application ("NDA") for intravitreal pegcetacoplan with the U.S. Food and Drug Administration ("FDA") for the treatment of geographic atrophy secondary to age-related macular degeneration in the second quarter of 2022; (ii) the acceptance of such NDA with priority review by the FDA; and (iii) receipt of approval of the NDA by the FDA by March 15, 2023 (collectively, the "2022 Performance Condition"). On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 2,471 shares of common stock, representing 25% of the shares underlying the PRSUs. The remaining shares underlying the PRSUs vest as to 25% on each anniversary of the grant date thereafter, subject to continued service.
- [F2]Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of PRSUs.
- [F3]The Reporting Person was granted performance-based stock options on January 21, 2022, the vesting of which was subject to the attainment of the 2022 Performance Condition. On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 25% of the shares underlying the option. The remaining shares underlying the option vest in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.